News >

Immunotherapy Shakes Up Gastric/GEJ Cancer Space, Alongside Angiogenic, Cytotoxic Agents

Caroline Seymour
Published: Thursday, Apr 04, 2019

J. Stuart Salmon, MD

J. Stuart Salmon, MD

Within gastric and gastroesophageal junction (GEJ) adenocarcinoma, strategies such as angiogenesis inhibition, cytotoxic therapy, and most recently, immunotherapy, are all beginning to have more refined roles in the treatment paradigm, explained J. Stuart Salmon, MD.

State of the Science Summit™ on Gastrointestinal Cancers, Salmon, a medical oncologist at the Levine Cancer Institute, highlighted first-, second-, and third-line treatment options for patients with gastric and GEJ cancer following recent clinical trial findings and regulatory approvals.

OncLive: What does the treatment landscape of gastric/GEJ cancer look like right now?

Salmon: There were several seminal papers in the past year. The first one was the TAGS study, in which investigators looked at the use of TAS-102 in patients with advanced gastric adenocarcinoma in the third-line setting. It was a positive stud; patients had improved OS and the treatment was found to be well tolerated.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication